---

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): October 20, 2003

 

 

CELL THERAPEUTICS, INC.

---

(Exact name of Registrant as specified in its charter)

 

 

Washington		0-28386		91-1533912
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

 

 

501 Elliott Avenue West, Suite 400

Seattle, WA 98119

---

(Address of principal executive offices) (Zip Code)

 

 

(206) 282-7100

---

(Registrant’s telephone number, including area code)

 

 

Not Applicable

---

(Former name or former address, if changed since last report.)

 

---

---

Item 5.  Other Events.

 

On October 20, 2003, Cell Therapeutics, Inc. issued a press release announcing that it had implemented a study amendment in its STELLAR 4 trial. The full text of the press release is set forth in Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 7.  Financial Statements and Exhibits.

 

(c)

Exhibits.

 

Exhibit		Description
99.1		Press release of Cell Therapeutics, Inc. issued on October 20, 2003.

 

2

---

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		CELL THERAPEUTICS, INC. a Washington corporation
October 20, 2003		By:		/s/ James A. Bianco, M.D.
				James A. Bianco, M.D. President and Chief Executive Officer

 

 

 

3

---

Index to Exhibits

 

Exhibit		Description
99.1		Press release of Cell Therapeutics, Inc. issued on October 20, 2003.

---

 

 

4